Camrelizumab is the third PD-1 drug made in China after toripalimab and sintilimab and can activate T cells by blocking PD-1/PD-L1 binding, thereby weakening the immunosuppression within the patients' organism and enhancing the tumor-killing effect [7, 8]. Here, CD274 is linked to neoplasm.